<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Safety concerns involved in post-authorisation amendments to aRMMs</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Type of amendment</th>
    <th align="left">Product concerned</th>
    <th align="left">Safety concern description</th>
    <th align="left">Source of evidence</th>
    <th align="left">Follow-up time (months)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="21">Introduction</td>
    <td align="left">ATryn
     <sup>©</sup>, Laboratoire Francais du Fractionnement et des Biotechnologies, France (antithrombin alfa)
    </td>
    <td align="left">Off-label use</td>
    <td align="left">Spontaneous reports</td>
    <td char="." align="char">137</td>
   </tr>
   <tr>
    <td align="left">Rotarix
     <sup>©</sup>, GlaxoSmithKline Biologicals S.A., Belgium (human rotavirus, live attenuated)
    </td>
    <td align="left">Administration error (accidental parenteral instead of oral)</td>
    <td align="left">Spontaneous reports</td>
    <td char="." align="char">63</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Cubicin
     <sup>©</sup>, Merck Sharp &amp; Dohme B.V., The Netherlands (daptomycin)
    </td>
    <td align="left">Skeletal muscle toxicity</td>
    <td align="left" rowspan="2">
     <p>Clinical trials</p>
     <p>Non-clinical studies</p>
    </td>
    <td char="." align="char" rowspan="2">118</td>
   </tr>
   <tr>
    <td align="left">Reduced susceptibility in 
     <italic>Staphylococcus aureus</italic>
    </td>
   </tr>
   <tr>
    <td align="left">Optimark
     <sup>©</sup>, Mallinckrodt Deutschland GmbH, France (gadoversetamide)
    </td>
    <td align="left">Nephrogenic systemic fibrosis</td>
    <td align="left">
     <p>Clinical trials</p>
     <p>Non-clinical studies</p>
     <p>Spontaneous reports</p>
    </td>
    <td char="." align="char">37</td>
   </tr>
   <tr>
    <td align="left">Vectibix
     <sup>©</sup>, Amgen Europe B.V., The Netherlands (panitumumab)
    </td>
    <td align="left">Lack of response and negative effects in combination with oxaliplatin-based chemotherapy in patients with mutant KRAS tumours</td>
    <td align="left">Clinical trials</td>
    <td char="." align="char">40</td>
   </tr>
   <tr>
    <td align="left">Evicel
     <sup>©</sup>, Omrix Biopharmaceuticals N.V., Belgium (human fibrinogen/human thrombin)
    </td>
    <td align="left">Air or gas embolism</td>
    <td align="left">Spontaneous reports</td>
    <td char="." align="char">23</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Effentora
     <sup>©</sup>, Teva B.V., The Netherlands (fentanyl)
    </td>
    <td align="left">Misuse, abuse and diversion</td>
    <td align="left" rowspan="3">Spontaneous reports</td>
    <td char="." align="char" rowspan="3">21</td>
   </tr>
   <tr>
    <td align="left">Use in patients who are not already receiving maintenance opioid therapy</td>
   </tr>
   <tr>
    <td align="left">Unintended (accidental) exposure</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Pandemrix
     <sup>©</sup>, GlaxoSmithKline Biologicals S.A., Belgium [split influenza virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain used NYMC X-179A]
    </td>
    <td align="left">Medical errors/misidentification of vaccine</td>
    <td align="left" rowspan="3">Spontaneous reports</td>
    <td char="." align="char" rowspan="3">17</td>
   </tr>
   <tr>
    <td align="left">Coring of the rubber stopper on the antigen vial</td>
   </tr>
   <tr>
    <td align="left">Contamination of multiple-dose vials</td>
   </tr>
   <tr>
    <td align="left">Pradaxa
     <sup>©</sup>, Boehringer Ingelheim International GmbH, Germany (dabigatran etexilate mesilate)
    </td>
    <td align="left">Haemorrhage</td>
    <td align="left">Clinical trials</td>
    <td char="." align="char">74</td>
   </tr>
   <tr>
    <td align="left">Vpriv
     <sup>©</sup>, Shire Pharmaceuticals Ireland Ltd, Ireland (velaglucerase alfa)
    </td>
    <td align="left">Infusion-related reactions</td>
    <td align="left">Observational studies</td>
    <td char="." align="char">71</td>
   </tr>
   <tr>
    <td align="left">Prolia
     <sup>©</sup>, Amgen Europe B.V., The Netherlands (denosumab)
    </td>
    <td align="left">Osteonecrosis of the jaw</td>
    <td align="left">
     <p>Clinical trials</p>
     <p>Observational studies</p>
     <p>Spontaneous reports</p>
    </td>
    <td char="." align="char">60</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Eliquis
     <sup>©</sup>, Bristol-Myers Squibb/Pfizer EEIG, Ireland (apixaban)
    </td>
    <td align="left">Bleeding</td>
    <td align="left" rowspan="3">Clinical trials</td>
    <td char="." align="char" rowspan="3">17</td>
   </tr>
   <tr>
    <td align="left">Severe renal or hepatic impairment</td>
   </tr>
   <tr>
    <td align="left">Liver injury</td>
   </tr>
   <tr>
    <td align="left">Xgeva
     <sup>©</sup>, Amgen Europe B.V., The Netherlands (denosumab)
    </td>
    <td align="left">Osteonecrosis of the jaw</td>
    <td align="left">
     <p>Clinical trials</p>
     <p>Observational studies</p>
     <p>Spontaneous reports</p>
    </td>
    <td char="." align="char">46</td>
   </tr>
   <tr>
    <td align="left">Rienso
     <sup>©</sup>, Takeda Pharma A/S, Denmark (ferumoxytol)
    </td>
    <td align="left">Hypersensitivity</td>
    <td align="left">Spontaneous reports</td>
    <td char="." align="char">26</td>
   </tr>
   <tr>
    <td align="left" rowspan="10">Discontinuation</td>
    <td align="left">Hirobriz Breezhaler
     <sup>©</sup>, Novartis Europharm Limited, Ireland (indacaterol maleate)
    </td>
    <td align="left">Off-label use</td>
    <td align="left">Observational studies</td>
    <td char="." align="char">93</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Renvela
     <sup>©</sup>, Genzyme Europe BV, The Netherlands (sevelamer carbonate)
    </td>
    <td align="left">Arteriovenous fistula site adverse drug reactions</td>
    <td align="left" rowspan="3">Unknown</td>
    <td char="." align="char" rowspan="3">96</td>
   </tr>
   <tr>
    <td align="left">Peritonitis</td>
   </tr>
   <tr>
    <td align="left">Vitamin deficiency</td>
   </tr>
   <tr>
    <td align="left" rowspan="5">Revolade
     <sup>©</sup>, Novartis Europharm Limited, Ireland (eltrombopag olamine)
    </td>
    <td align="left">Hepatotoxicity</td>
    <td align="left" rowspan="5">Unknown, considered part of clinical practice</td>
    <td char="." align="char" rowspan="5">87</td>
   </tr>
   <tr>
    <td align="left">Thromboembolic events</td>
   </tr>
   <tr>
    <td align="left">Post therapy reoccurrence of thrombocytopenia</td>
   </tr>
   <tr>
    <td align="left">Potential for increase in bone marrow reticulin formation</td>
   </tr>
   <tr>
    <td align="left">Haematological malignancies</td>
   </tr>
   <tr>
    <td align="left">HyQvia
     <sup>©</sup>, Baxalta Innovations GmbH, Austria (human normal immunoglobulin)
    </td>
    <td align="left">Safety in pregnant and lactating women</td>
    <td align="left">Non-clinical studies</td>
    <td char="." align="char">25</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>aRMMs</italic> additional risk minimisation measures
  </p>
 </table-wrap-foot>
</table-wrap>
